The Clinical Study On The Efficacy Ofintensive Lipid-lowering Therapy In Patients With Non-ST-segment Elevation Acute Coronary Syndromes

Objective:To study the clinical efficacy and safety of atorvastatin (40mg/day) in patients with non-ST-segmentelevation acute coronary syndromes (NSTE-ACS).Methods:From January2008to December2010,68cases of NSTE-ACS patients, were randomly divided into treatment group34cases and the control group34cases.Two groups of patients had conventional treatment(aspirin, isosorbide mononitrate, clopidogrel, etc.).Patients in the treatment group took atorvastatin40mg per day for one month, then20mg to maintain, while patients in the control group took atorvastatin10mg per day at all time.The course of treatment lasted6months. Blood cholesterol, liver function, high reactive c-reactive protein (hs-CRP) changes were recorded before treatments and after1month,3months,6months of treatments. Anginapectoris as well as serious cardiovascular events(recurrence myocardial infarction,cardic death,severe heart failure,ect), were also recorded.Results:The total cholesterol, low density lipoprotein cholesterol(LDL-C) and hs-CRP were significantly improved in both two groups after6months of treatment (P<0.05or0.01). The incidenceof adverse cardiovascular events was significantly lower in intensive group during treatment (P<0.05). Frequency and duration of angina pectoris were also decreased in both groups (P<0.05), especially in intensive group (P<0.05).Lower incidence of adverse cardiovascular events was found after discharge from hospital in intensive group (P<0.01).Conclusion:Intensive lipid-lowering therapy with atorvastatin in NSTE-ACS patients who did not receive reascularization treatment can obviously improve the clinical symptoms, reduce the complications and serious cardiovascular events.And a large dose of atorvastatin can gain greater benefits and is also safety.